First mRNA cancer vaccine succeeds in late-stage trial, reshaping treatment

An mRNA cancer vaccine has achieved success in a late-stage clinical trial for the first time, marking a potential paradigm shift in oncology. The specific cancer type and efficacy data are not detailed, and regulatory approval and broad clinical adoption remain uncertain. This development could significantly alter cancer treatment protocols and preventive strategies, with major implications for public health and pharmaceutical markets.